Format

Send to

Choose Destination
Epigenomics. 2015;7(8):1303-11. doi: 10.2217/epi.15.77. Epub 2015 Dec 7.

Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives.

Author information

1
Department of Molecular Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA.
2
Department of Cell Research & Immunology, George S. Wise, Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.
3
Brain Tumor Center, Providence Saint John's Health Center, Santa Monica, CA 90404, USA.

Abstract

Melanoma brain metastasis is a complication with rising incidence. Despite the high rate of somatic mutations driving the initial stages of melanocyte transformation, the brain colonization requires a phenotypic reprogramming that is, in part, influenced by epigenomic modifications. This special report summarizes recent findings in the epigenomic landscape of melanoma progression to brain metastasis, with particular emphasis on the clinical utility of DNA methylation, chromatin modifications and ncRNA expression as theragnostic markers, as well as the significance of the metastatic microenvironment on melanoma brain metastasis epigenome.

KEYWORDS:

DNA methylation; cancer progression; chromatin modifications; epigenomics; melanoma brain metastasis; metastasis microenvironment; noncoding RNA expression; regulatory elements

PMID:
26638944
DOI:
10.2217/epi.15.77
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center